This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Close
Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Avastin® (bevacizumab)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼(pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozyltrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Immunology
      • RoACTEMRA® (tocilizumab)
      • Haematology
      • Gazyvaro® (obinutuzumab)
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab)
      • Esbriet® (pirfenidone)
      • GAZYVARO® (obinutuzumab)
      • HEMLIBRA®▼(emicizumab)
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab)
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • RoACTEMRA® (tocilizumab) RA/GCA
      • RoACTEMRA® (tocilizumab) pJIA/sJIA
      • RoACTEMRA® (tocilizumab) CRS
      • Rozlytrek® ▼(entrectinib)
      • Tecentriq®▼ (atezolizumab) HCC
      • Tecentriq®▼ (atezolizumab) Lung Cancer
      • Tecentriq®▼ (atezolizumab) mTNBC
      • Tecentriq®▼ (atezolizumab) mUC
    • Adverse Events Reporting
      Adverse Events Reporting Overview
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    • Congress Highlights

      Watch the key highlights from the ECTRIMS 2019 congress chosen by the Steering Committee.

      Read more


    You are here:

    1. Resources
    2. Congresses and Meetings
    3. ECTRIMS 2019
    ECTRIMS 2019 11 September 13 September
    Stockholm
    Stockholm Sweden

    ECTRIMS Annual Meeting

    The Roche MS Steering Committee share their thoughts on the importance of the ECTRIMS Annual Meeting and some of their key learnings from this year's meeting that they thought were most relevant to share with the UK clinical community. For details of the content presented please view the ECTRIMS 2019 MS Highlights Report. 

    Committee Members

    • Professor Jeremy Hobart, Consultant Neurologist, University Hospitals Plymouth NHS Trust (Project co-chair)
    • Dr Niraj Mistry, Consultant Neurologist, Queen Elizabeth Hospital, Birmingham (Project co-chair)
    • Dr Tom Button, Consultant Neurologist, York Hospital
    • Ms Rachel Dorsey-Campbell, Neurological Pharmacist, Imperial College Healthcare NHS Trust
    • Dr Paul Gallagher, Consultant Neurologist, Institute of Neurological Sciences, Glasgow
    • Dr Tim Harrower, Consultant Neurologist, Royal Devon and Exeter NHS Foundation Trust
    • Dr Oliver Lily, Consultant Neurologist, Leeds General Infirmary
    • Dr Monica Marta, Consultant Neurologist, Barts Health NHS Trust/QMUL
    • Dr Gemma Maxwell, Neuro-Ophthalmology Fellow, Royal Victoria Infirmary, Newcastle-upon-Tyne
    • Dr Heather Wilson, Consultant Neurologist, Royal Free London, NHS Trust

    These individuals share a range of interests within the field of MS and represent a geographic spread of MS expertise across the UK.

    ECTRIMS 2019 – Key Highlights

    Professor Jeremy Hobart, Ms Rachel Dorsey-Campbell, Dr Niraj Mistry & Dr Tim Harrower reflect on the neurology updates they found most interesting at ECTRIMS 2019, and comment on how these findings may impact UK clinical practice, both now and in the future. Here they discuss:

    • Updated data from several studies investigating treatments available for MS in progressive phases
    • Implications on healthcare systems capacity
    • A hot topic at ECTRIMS - vitamin D. Which dose do they recommend? 

    Please click here to view the ECTRIMS 2019 Highlights Report.

    ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis, MS; multiple sclerosis.

     

    M-GB-00000983

    Date of preparation: August 2020

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2021 Roche Products Limited
    • 19.01.2021
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00002434 Date of Preparation January 2021.